Neurocrine Bioscienc (NBIX)

$NBIX = been a little weak here lately... but not for long. 👍🙃

B of A Securities updates rating for Neurocrine Biosciences ( $NBIX ) to Buy, target set at 182 → 184.

B of A Securities has adjusted their stance on Neurocrine Biosciences ( $NBIX ), setting the rating to Buy with a target price of 172 → 182.

$RDDT $HOOD $NVDA $AVGO $NBIX we will comeback next week with fresh mind. Too much to take today from the White House. Boy today wasn’t there

Guggenheim has updated their rating for Neurocrine Biosciences ( $NBIX ) to Buy with a price target of 175.

$NBIX temporary dip for sure.

JP Morgan has updated their rating for Neurocrine Biosciences ( $NBIX ) to Neutral with a price target of 145.

$NBIX Chart suggests down we go. Will the 200 day hold over time or will it test $115. Will we EVER breakout? It has been YEARS! It's really brutal.

Morgan Stanley has adjusted their stance on Neurocrine Biosciences ( $NBIX ), setting the rating to Overweight with a target price of 150 → 158.

$TEVA Thought you might like to see. $INCY $GMAB $RDY $NBIX

$NBIX reported 1.06 EPS and 687.50 revenue for Q2. http://www.estimize.com/intro/nbix?chart=historical&metric_name=eps&utm_content=NBIX&utm

$NBIX no real surpises in ER imo. Ingrezza guidance down a little bit, crenessity sales growing nicely. Overall very promising imo

$NBIX - Neurocrine Biosciences Inc. Common Stock - 10Q - Updated Risk Factors NBIX’s 10-Q risk update flags heightened exposure to healthcare reform, drug pricing controls, Inflation Reduction Act impacts, rapid commercial growth challenges, IP risks, expanded market acceptance hurdles, regulatory uncertainty post-Supreme Court ruling, supply chain and geopolitical risks, and increased financial, cybersecurity, and international trade pressures. #HealthcareReform #SupplyChainRisks #IntellectualPropertyRisks #InflationReductionAct #DrugPricingControls 🟢 Added 🟠 Removed https://d-risk.ai/NBIX/10-Q/2025-07-30

$NBIX Neurocrine Biosciences Q2 Adj. EPS $1.65 Beats $0.95 Estimate, Sales $687.500M Beat $652.637M Estimate

$NBIX will rip to the upside tomorrow 💸

$NBIX 🐒🍌🧠⏰♾️

$NBIX reports after the close, Estimize Consensus +0.21 EPS and +3.21M Revs compared to WS http://www.estimize.com/nbix/fq2-2025?utm_conten

$NBIX back to 52 week highs in play

$NBIX Heads up alert! Upcoming earnings on Wednesday, 7/30/2025 for $NBIX Bullish (7.4) Financial Analysis: Neurocrine Biosciences, Inc. (NBIX) is showcasing promising growth potential, reinforced by its recent strategic developments and clinical advancements. The company's P/E ratio indicates a fair valuation compared to industry peers, suggesting that the stock is not overvalued given its growth prospects. Earnings per share (EPS) are projected to grow, reflecting the company's robust pipeline and successful product launches. Revenue forecasts remain optimistic, driven by the strong performance of INGREZZA® (valbenazine) and the promising data from its CAHtalyst™ studies for congenital adrenal hyperplasia. Compared to its industry peers, Neurocrine is well-positioned, with a focus on niche markets and advanced therapeutics that address unmet medical needs. Its strong balance sheet, characterized by being debt-free, provides a solid foundation for future growth and strategic investments. Upcoming Earnings Report Summary: Neurocrine Biosciences is scheduled to release its second-quarter 2025 financial results shortly. Historically, the company has demonstrated steady financial performance, with consistent revenue growth and strategic advancements in its clinical programs. Analyst consensus estimates suggest cautious optimism, with expectations of continued EPS growth driven by product sales and pipeline progress. While previous earnings reports have occasionally missed expectations, the current market sentiment and recent data releases suggest the potential for positive surprises. The upcoming earnings will be pivotal in affirming the company's strategic trajectory and could impact the stock's performance significantly, especially if results align with or exceed market expectations. Sector Performance Context: The biotechnology sector, to which Neurocrine Biosciences belongs, has been experiencing a mixed performance recently, influenced by broader market conditions, including inflationary pressures and regulatory challenges. However, the sector remains a focal point for investors due to its innovation-driven growth potential and the ongoing demand for novel therapeutics. Within this context, Neurocrine's focus on rare diseases and specialized treatments positions it favorably, enabling the company to capitalize on sector trends and maintain a competitive edge. The sector's future outlook remains cautiously optimistic, with significant opportunities for companies that demonstrate strong clinical and commercial execution. - Funds were net buyers of $NBIX during the previous reporting quarter. - Funds with large holdings in $NBIX: - Deerfield Management Co, MV: $165MM. Fund Rank: 94% www.deerfield.com - Armistice Capital LLC, MV: $111MM. Fund Rank: 80% www.armisticecapital.com - OrbiMed Advisors LLC, MV: $103MM. Fund Rank: 60% www.orbimed.com - IEQ Capital LLC, MV: $59MM. Fund Rank: 77% - GW&K Investment Management LLC, MV: $57MM. Fund Rank: 81% - Last 10 days performance: 0% - Last 30 days performance: 6% - Last 90 days performance: 26% Some of the latest news articles: - Title: Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Publication Date: 7/24/2025 2:00:32 PM, Source: yahoo URL: https://finance.yahoo.com/news/indivior-plc-indv-expected-beat-140032679.html?.tsrc=rss - Title: High Growth Tech Stocks In US To Watch July 2025 Publication Date: 7/23/2025 5:38:24 PM, Source: yahoo URL: https://finance.yahoo.com/news/high-growth-tech-stocks-us-173824627.html?.tsrc=rss - Title: Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Publication Date: 7/23/2025 2:00:31 PM, Source: yahoo URL: https://finance.yahoo.com/news/neurocrine-biosciences-nbix-earnings-expected-140031934.html?.tsrc=rss - Title: Neurocrine shares new one-year data from trial of Crenessity for CAH Publication Date: 7/15/2025 2:57:26 PM, Source: yahoo URL: https://www.clinicaltrialsarena.com/news/neurocrine-crenessity-cah/?.tsrc=rss Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal.

$NBIX in HRMY n RYTM out of the tightness 🐒🍌🧠⏰♾️

Cantor reiterated $NBIX Overweight/$170. W/ $NBIX reporting 2Q25 next Thurs—Cantor notes volatility around earnings (both⬆️&⬇️; avg 6%), over the last few yrs—but points to the last 3 years, 75% of $NBIX earning prints have seen shares trade higher. $CRNX $BMY $TEVA $PTCT Cantor said in its note: " $NBIX reports 2Q25 next Thursday - shares tend to be volatile around earnings, with avg moves of~6% (either up or down) over the past few years. While we generally feel good about Crenessity (high confidence) and Ingrezza (low/medium confidence), we note that the volatility and imprecision predicting quarterly earnings results for $NBIX keeps us on our toes. Each of the last 4 earnings reports have seen stock moves over 5% (either direction). Over the last 3 years, 75% of $NBIX earning prints have seen shares trade higher, so at least the earnings odds are favorable. 1Q25 saw an 8% bounce in shares after the -18% move down in 4Q24 (due to disappointing '25 guidance)."